Global Information
회사소개 | 문의
SALE

손발톱진균증 : 주요 22개국 시장 예측

EPIOMIC EPIDEMIOLOGY SERIES: ONYCHOMYCOSIS FORECAST IN 22 MAJOR MARKETS 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 07월 상품 코드 339846
페이지 정보 영문 100 Pages
가격
US $ 5,800 US $ 5,104 ₩ 5,820,000 PDF by E-mail (Single User License)
US $ 8,700 US $ 7,656 ₩ 8,730,000 PDF by E-mail (Site License)
US $ 10,400 US $ 9,152 ₩ 10,436,000 PDF by E-mail (Global License)


손발톱진균증 : 주요 22개국 시장 예측 EPIOMIC EPIDEMIOLOGY SERIES: ONYCHOMYCOSIS FORECAST IN 22 MAJOR MARKETS 2018-2028
발행일 : 2018년 07월 페이지 정보 : 영문 100 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

손발톱진균증(조갑진균증)은 손톱·발톱에 발생하는 진균류 감염증입니다. 잘 알려진 병원체로 적색백선균 및 모창백선균 등의 균류 병원체를 들 수 있습니다. 또, 주요 병존증은 당뇨병, 족부백선, 말초혈관 질환, HIV/AIDS, 건선, 고콜레스테롤혈증, 뼈관절 질환 등이 있습니다.

세계 주요 22개국의 손발톱진균증(ONYCHOMYCOSIS) 발증 상황에 대해 분석했으며, 질환 개요와 현재 환자수, 성별·연령 그룹별(5세 단위 그분) 상황, 지역별·민족별 동향, 위험인자, 질환 진단과 예후, 주요 증상과 합병증, 향후 동향 전망(향후 10년간) 등의 정보를 정리하여 전해드립니다.

1. 목차

  • 도표
  • 서론
  • 질환 원인
  • 위험인자와 예방법
  • 질환 진단
  • 지역별/민족별 차이
  • 질환 예후와 임상 경과
  • 질환에 관련된 주요 병존증/특징
  • 환자수 정량화 방법
  • 손발톱진균증 최대 환자수
  • 손발톱진균증 환자의 특징
    • 분류, 병인, 징후
  • 손발톱진균증 환자의 주요 병존증
  • 참고 문헌
  • 부록

2. 분석 대상국

  • 미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 스웨덴, 덴마크, 핀란드, 러시아, 터키, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나
LSH 18.07.12

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Onychomycosis in 22 Major Markets

Onychomycosis is a fungal infection of the nail which occurs in the hands or feet. The more notable causative agents include the fungal pathogens Trichophyton rubrum and Trichophyton mentagrophytes. This report provides the current prevalent population for Onychomycosis across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Denmark, Finland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patient groups divided by disease classification, aetiology, main symptoms and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Onychomycosis include:

Diabetes

Tinea pedis

Peripheral vascular disease

HIV / AIDS

Psoriasis

Hypercholesterolaemia

Osteoarticular disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Onychomycosis market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Onychomycosis and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Useful in the identification and trend of the prevalence numbers for the different causative agents of Onychomycosis.

Provide a level of understanding on the impact from specific co-morbid conditions on Onychomycosis prevalent population.

Identify sub-populations within Onychomycosis which require treatment.

Gain an understanding of the specific markets that have the largest number of Onychomycosis patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR ONYCHOMYCOSIS
  • FEATURES OF ONYCHOMYCOSIS PATIENTS
  • CLASSIFICATION
  • AETIOLOGY
  • SIGNS
  • COMORBIDITIES OF ONYCHOMYCOSIS PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Definition of main onychomycosis types
  • Table 2. Prevalence of onychomycosis, total (000s)
  • Table 3. Prevalence of onychomycosis, males (000s)
  • Table 4. Prevalence of onychomycosis, females (000s)
  • Table 5. Patients with clinically diagnosed onychomycosis, total (000s)
  • Table 6. Clinically diagnosed onychomycosis patients with current active infection, total (000s)
  • Table 7. New cases of clinically diagnosed onychomycosis per year, total (000s)
  • Table 8. Patients with clinically diagnosed onychomycosis by site of infection, total (000s)
  • Table 9. Patients with clinically diagnosed onychomycosis by major clinical presentation type, total (000s)
  • Table 10. Patients with clinically diagnosed DLSO by severity, total (000s)
  • Table 11. Patients with clinically diagnosed onychomycosis by duration of disease, total (000s)
  • Table 12. Patients with clinically diagnosed onychomycosis by causative agent, total (000s)
  • Table 13. Patients with clinically diagnosed dermatophyte onychomycosis by type, total (000s)
  • Table 14. Patients with clinically diagnosed non-dermatophyte onychomycosis by type, total (000s)
  • Table 15. Patients with clinically diagnosed yeast onychomycosis by type, total (000s)
  • Table 16. Patients with clinically diagnosed mould onychomycosis by type, total (000s)
  • Table 17. Clinically diagnosed onychomycosis patients with signs of infection, total (000s)
  • Table 18. Clinically diagnosed onychomycosis patients with skin discolouration, total (000s)
  • Table 19. Clinically diagnosed onychomycosis patients with hyperkeratosis, total (000s)
  • Table 20. Clinically diagnosed onychomycosis patients with onycholysis, total (000s)
  • Table 21. Clinically diagnosed onychomycosis patients with damaged nail, total (000s)
  • Table 22. Clinically diagnosed onychomycosis patients with paronychia, total (000s)
  • Table 23. Clinically diagnosed onychomycosis patients with diabetes, total (000s)
  • Table 24. Clinically diagnosed onychomycosis patients with tinea pedis, total (000s)
  • Table 25. Clinically diagnosed onychomycosis patients with tinea pedis by subtype, total (000s)
  • Table 26. Clinically diagnosed onychomycosis patients with tinea pedis by causative agent, total (000s)
  • Table 27. Tinea pedis patients with recurrent onychomycosis, total (000s)
  • Table 28. Abbreviations and acronyms used in the report
  • Table 29. USA prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 30. USA prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 31. Canada prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 32. Canada prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 33. France prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 34. France prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 35. Germany prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 36. Germany prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 37. Italy prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 38. Italy prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 39. Spain prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 40. Spain prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 41. UK prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 42. UK prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 43. Poland prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 44. Poland prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 45. Netherlands prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 46. Netherlands prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 47. Sweden prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 48. Sweden prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 49. Denmark prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 50. Denmark prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 51. Finland prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 52. Finland prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 53. Russia prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 54. Russia prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 55. Turkey prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 56. Turkey prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 57. Japan prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 58. Japan prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 59. China prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 60. China prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 61. South Korea prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 62. South Korea prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 63. India prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 64. India prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 65. Australia prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 66. Australia prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 67. Brazil prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 68. Brazil prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 69. Mexico prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 70. Mexico prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Table 71. Argentina prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Table 72. Argentina prevalence of onychomycosis by 5-yr age cohort, females (000s)
Back to Top
전화 문의
이용안내
 
BCC Research